Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
65.50    -0.50 (-0.76%)
Bid:
65.00
Ask:
66.00
Spread: 1.00 (1.538%)
Market Cap: £79.80m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

New distribution agreements

23 Sep 2014 07:00

RNS Number : 3099S
Venture Life Group PLC
23 September 2014
 

 

Venture Life Group plc

("Venture Life" or "the Group")

Long-term distribution agreements signed with four new partners

 

Bracknell, UK - 23 September 2014: Venture Life Group plc (AIM: VLG), the international consumer self-care group addressing the needs of the ageing population, announces that it has signed long-term product distribution agreements with four new partners. The agreements give these distributors exclusive rights to sell certain Venture Life products across a total of nine European territories, including Germany. Based on the contractual minimum purchase obligations of the partners, these four agreements combined should deliver minimum annual revenues of €0.24 million in year 1, rising to €0.59 million in year 5, and totalling €5.1 million over the ten year term of the agreements.

 

The agreements are with the following companies:

 

Distributor

Venture Life product

Territories

Expected first revenues for VLG

Valeant

Procto-eze cream

Six, including Germany

H1 2015

Lyfis

Procto-eze cream and cleanser

Iceland

H1 2015

Symphar

Procto-eze cream

Poland

H1 2015

Deltapharma

Original Bioscalin shampoo and capsules

Albania

H1 2015

 

In addition to these agreements, the Group has already signed a further seven product partnering deals during 2014, as well as four extension deals signed with existing partners for additional Venture Life products. The Group now has distribution agreements covering all 14 of its current branded products in a combined 42 territories worldwide, and its unbranded products manufactured by Biokosmes are sold in over 10 countries.

Jerry Randall, Chief Executive Officer of Venture Life, commented:

"We are delighted to broaden further our partner base in Europe, and to see further validation of our model and products through a long term agreement with Valeant, a global top 50 pharmaceutical company. We are delivering increasing benefits from the merger with Biokosmes and are seeing gathering momentum in our branded portfolio as we broaden the distribution base of our branded products. We are particularly pleased with our first distribution deal in Germany, the fourth largest economy in the world and a major European territory".

 

- Ends -

 

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer +44 (0)1344 742 870

 

 

Square1 Consulting

David Bick

Mark Longson +44 (0)20 7929 5599

 

 

JW Communications

Julia Wilson +44 (0)7818 430877

 

 

Notes to editors

 

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercializing products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its topical development and manufacturing business, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 50 countries and currently include:

· food supplements to maintain brain function and memory;

· dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

· medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

 

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

About Procto-eze

Procto-eze helps relieve the discomfort caused by haemorrhoids.

 

About Original Bioscalin

Original Bioscalin helps control hair loss, promotes new hair growth and enhances the overall condition of hair.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADLLFLZKFFBBX
Date   Source Headline
30th Jan 20264:42 pmRNSExercise of Share Options & Total Voting Rights
30th Jan 20267:00 amRNSTransaction in Own Shares
29th Jan 20267:00 amRNSTransaction in Own Shares
28th Jan 20267:00 amRNSTransaction in Own Shares
27th Jan 20267:00 amRNSTransaction in Own Shares
26th Jan 20267:30 amRNSTransaction in Own Shares
26th Jan 20267:00 amRNSTrading Update
23rd Jan 20267:00 amRNSTransaction in Own Shares
22nd Jan 20267:00 amRNSTransaction in Own Shares
21st Jan 20267:00 amRNSTransaction in Own Shares
20th Jan 20267:00 amRNSExercise of Share Options & Total Voting Rights
19th Jan 20267:00 amRNSTransaction in Own Shares
16th Jan 20267:00 amRNSTransaction in Own Shares
15th Jan 20267:00 amRNSTransaction in Own Shares
14th Jan 20267:00 amRNSTransaction in Own Shares
13th Jan 20267:00 amRNSTransaction in Own Shares
12th Jan 20267:00 amRNSTransaction in Own Shares
9th Jan 202611:27 amRNSDirector/PDMR Shareholding
9th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20267:00 amRNSTransaction in Own Shares
7th Jan 20267:00 amRNSTransaction in Own Shares
2nd Jan 20264:30 pmRNSTotal Voting Rights
2nd Jan 20267:00 amRNSExercise of Options, Director Dealings & TVR
2nd Jan 20267:00 amRNSExercise of Options, Director Dealings & TVR
31st Dec 20257:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
30th Dec 20257:00 amRNSTransaction in Own Shares
30th Dec 20257:00 amRNSTransaction in Own Shares
24th Dec 20257:00 amRNSTransaction in Own Shares
23rd Dec 20257:00 amRNSTransaction in Own Shares
23rd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 20257:00 amRNSTransaction in Own Shares
18th Dec 20254:18 pmRNSExercise of Share Options & Total Voting Rights
18th Dec 20254:18 pmRNSExercise of Share Options & Total Voting Rights
17th Dec 20254:21 pmRNSHolding(s) in Company
17th Dec 20254:19 pmRNSHolding(s) in Company
17th Dec 20257:00 amRNSTransaction in Own Shares
16th Dec 20257:00 amRNSTransaction in Own Shares
15th Dec 20257:00 amRNSTransaction in Own Shares
12th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20257:00 amRNSSale of Non-Core Products
8th Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20254:30 pmRNSTotal Voting Rights
1st Dec 20257:00 amRNSTransaction in Own Shares
28th Nov 20257:00 amRNSTransaction in Own Shares
25th Nov 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.